- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03362073
Kontinuerlig intravenös infusion av ketamin hos terminalt sjuka cancerpatienter (CIVIK)
En fas II-studie om effektivitet och säkerhet av den kontinuerliga intravenösa infusionen av ketamin hos terminalt sjuka cancerpatienter med refraktär cancersmärta
To establish the role of ketamine in hospitalized terminally ill cancer patients with refractory cancer pain, using continuous intravenous infusion of ketamine
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
- There are approximately 20 percent patients of refractory cancer pain, which is troubled with uncontrolled pain though treatment including opioids.
- Ketamine has been showed the performance of Ketamine, N-methyl-D-aspartate (NMDA) receptor blocker, in refractory cancer pain based on prior studies.
- We cannot yet confirm the role of Ketamine comparing the benefit and risk due to incompatible results of prior studies. Additionally, most of prior studies were studied in heterogenous groups, which are from beginning of palliative chemotherapy to terminal status, so role of ketamine was not assessed in homogeneous terminally ill cancer patients. And they has used mostly 'bolus intravenous infusion' or 'continuous subcutaneous infusion (CSCI)', relatively rare in continuous intravenous infusion (CIVI).
- The bolus intravenous method is convenient but is concerned with leading to relatively severe adverse events due to poor general condition of terminally ill cancer patients, the CSCI method is not recommended because of adverse events (AEs) such as skin irritation. On the contrary, the CIVI method using gradual increasing ketamine minimizes AEs and is free of skin irritation. Most of hospitalized terminally ill cancer patients has proper IV access using intravascular devices (chemoport or PICC). So, CIVI method is suitable to hospitalized terminally ill cancer patients.
- This study assess the efficacy and safety of 5-days CIVI gradual dose titration of Ketamine in terminally ill cancer patients with refractory cancer pain.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
Gyeongsangnam-do
-
Yangsan, Gyeongsangnam-do, Sydkorea, 50612
- Pusan National University Yangsan Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Among patients with histologically or cytologically confirmed malignancy, patients with expected survival time of several months or less due to a progressive disease without additional anticancer treatment.
- Patients with refractory cancer pain, which cases of requesting 4 or more breakthrough analgesics or increase of baseline analgesics (average pain score ≥ 4 or Personalized pain goal) in spite of 120 mg/day or more of intravenous Morphine Equivalent Daily Dose
- Hospitalized patients with intravascular access during at least 5 days
- Age 18 or older
- Signed and dated informed consent of document indicating that the patient (or legally acceptable representative) has been informed about all pertinent aspects of the trial prior to enrollment
Exclusion Criteria:
-
Patients who were treated with ketamine for pain control within 6 months
-
Patients who have been treated with radiotherapy within 4 weeks or plan to intervention for pain control during study period
-
Cancer pain cannot be excluded the Opioid induced hyperalgesia
-
Concomitant severe medical, surgical, or disease or problems which were contraindicated to application of Ketamine or have possibilities of unexpected medical problems caused be the Ketamine
- confirmed or assumed central nervous system lesion which lead to increased intracranial pressure
- Arrhythmia (supra-ventricular tachycardia, ventricular arrhythmia (frequent premature ventricular contraction, bigeminy, Ventricular tachycardia)
- history of hemorrhagic stroke or seizure within 3 months
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Ketamine
continuous intravenous infusion of ketamine |
Application of ketamine using continuous intravenous infusion method during 5 days
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Overall response rate
Tidsram: From date of enrollment until 5 days or drop-out, assess up to 2 years
|
complete pain response plus partial pain response
|
From date of enrollment until 5 days or drop-out, assess up to 2 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change of pain intensity
Tidsram: From date of enrollment until 5 days or drop-out, assess up to 2 years
|
Delineate changes of pain intensity daily, from the time baseline until 5th days after application of ketamine. Pain intensity is defined as the mean of terdiurnal checked patient reported pain score during a day. |
From date of enrollment until 5 days or drop-out, assess up to 2 years
|
|
Rescue analgesics for breakthrough pain
Tidsram: From date of enrollment until 5 days or drop-out, assess up to 2 years
|
Dose and number of rescue analgesics for breakthrough pain |
From date of enrollment until 5 days or drop-out, assess up to 2 years
|
|
Patient's satisfaction about Ketamine by a newly developed question in this study
Tidsram: at the 5th days or drop-out, assess up to 2 years
|
Satisfaction about pain control and Ketamine-related distress during application of ketamine was evaluated by questions as follows: "How do you feel satisfaction about ketamine?" (at 5th days or drop-out) |
at the 5th days or drop-out, assess up to 2 years
|
|
Guardian's satisfaction about Ketamine by a newly developed question in this study
Tidsram: at the 5th days or drop-out, assess up to 2 years
|
Satisfaction about pain control and Ketamine-related distress during application of ketamine was evaluated by questions as follows: "How do you feel satisfaction about ketamine?" (at 5th days or drop-out) |
at the 5th days or drop-out, assess up to 2 years
|
|
Rate of Ketamine-related adverse events
Tidsram: From date of enrollment until 5 days or drop-out, assess up to 2 years
|
Rate of Ketamine-related adverse events |
From date of enrollment until 5 days or drop-out, assess up to 2 years
|
|
Rate of early discontinuation
Tidsram: From date of enrollment until 5 days or drop-out, assess up to 2 years
|
Rate of discontinuation due to Ketamine related AEs |
From date of enrollment until 5 days or drop-out, assess up to 2 years
|
|
Overall survival
Tidsram: From date of enrollment until death or discharge/transfer, assess up to 2 years
|
Time from application of ketamine until death or discharge/transfer |
From date of enrollment until death or discharge/transfer, assess up to 2 years
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Kwonoh Park, MD, PhD, Pusan National University Yangsan Hospital
Publikationer och användbara länkar
Allmänna publikationer
- van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007 Sep;18(9):1437-49. doi: 10.1093/annonc/mdm056. Epub 2007 Mar 12.
- Zech DFJ, Grond S, Lynch J, Hertel D, Lehmann KA. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain. 1995 Oct;63(1):65-76. doi: 10.1016/0304-3959(95)00017-M.
- Hanks GW, Justins DM. Cancer pain: management. Lancet. 1992 Apr 25;339(8800):1031-6. doi: 10.1016/0140-6736(92)90546-f. No abstract available.
- Hardy J, Quinn S, Fazekas B, Plummer J, Eckermann S, Agar M, Spruyt O, Rowett D, Currow DC. Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. J Clin Oncol. 2012 Oct 10;30(29):3611-7. doi: 10.1200/JCO.2012.42.1081. Epub 2012 Sep 10.
- Jackson K, Ashby M, Martin P, Pisasale M, Brumley D, Hayes B. "Burst" ketamine for refractory cancer pain: an open-label audit of 39 patients. J Pain Symptom Manage. 2001 Oct;22(4):834-42. doi: 10.1016/s0885-3924(01)00340-2.
- Mercadante S, Arcuri E, Tirelli W, Casuccio A. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage. 2000 Oct;20(4):246-52. doi: 10.1016/s0885-3924(00)00194-9.
- Bell RF, Eccleston C, Kalso EA. Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev. 2017 Jun 28;6(6):CD003351. doi: 10.1002/14651858.CD003351.pub3.
- Park K, Kim JJ, Oh SB, Oh SY, Hong YJ, Kim SJ, Park EJ, Choi N, Shin SH, Kim S, Ko H. A Phase II Study About Efficacy and Safety of the Continuous IntraVenous Infusion of Ketamine as Adjuvant to Opioids in Terminally Ill Cancer Patients With Refractory Cancer Pain (CIVIK Trial). Am J Hosp Palliat Care. 2025 Mar;42(3):244-252. doi: 10.1177/10499091241252977. Epub 2024 May 16.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- CIVIK
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .